Vertex Pharmaceuticals, a cystic fibrosis powerhouse, is sprinting into new medical territories with big ambitions. The ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

In this interview, Yifan Guo, a second-year graduate student studying and teaching mathematics at Brown University, shares ...

As lawmakers draw hard lines over what they will support in the ... further complicating the fiscal math. Each group has outsized influence because of Republicans' narrow majorities in both ...

Dividing line: How middle school math sets students up for success, and how we lose them Lack of advanced math options limits many Ohio high schoolers' education Ohio colleges are rethinking ...

Now apply that to the U.S. economy. The trade deficit is a cost. But trying to slash costs while suffocating the top line — the country’s demand engine — is a fast track to economic self ...

Aaron Dye is the director of the short documentary “Taha’s Theorem,” which make its world premiere at the 2025 Thin Line Festival on ... the world’s hardest math problems, both to bring ...

But I think the most inviting targets right now are still the elite privates—and then the big blue-state public universities: UC–Berkeley, UCLA, Michigan, Rutgers. I think they’re next in line.

KING OF PRUSSIA, Pa. - Vertex (NASDAQ:VRTX), Inc. (NASDAQ:VERX) shares tumbled 15.4% after the indirect tax solutions provider reported in-line fourth quarter results but issued disappointing guidance ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel non-opioid pain medication. This approval marks ...

were trading largely flat post-market Monday after the biotech company released its Q4 earnings report and issued 2025 guidance that was largely in line with Street expectations. For Q4, Vertex ...